Alliance for the Prudent Use of Antibiotics
The mission of the Alliance for the Prudent Use of Antibiotics (APUA) is to strengthen global defenses against infectious disease by ensuring access to effective treatment and promoting appropriate antibiotic use to contain drug resistance. With a network of affiliated chapters in 19 countries, APUA stands as the world’s leading organization conducting research and education on antimicrobial treatment and resistance at the grassroots and global levels.
The Alliance for the Prudent Use of Antibiotics (APUA) and the International Society of Antimicrobial Chemotherapy (ISAC) are very sad to pass on the news that Professor Stuart Levy passed away on Wednesday 4 September 2019 after an extended illness. He would have turned 81 in November.
Stuart B. Levy M.D. was both a physician and researcher. He was Professor of Molecular Biology and Microbiology and of Medicine and Director of the Center for Adaptation Genetics and Drug Resistance at Tufts University School of Medicine in Boston. Amongst the many offices he held, he was a past President of the American Society of Microbiology (ASM) and founder of APUA which he served as President until very recently.
Stuart Levy was best known for his work on antibiotic resistance. His 1976 prospective farm study showing that antibiotic resistance elements can be transferred from intestinal flora of farm animals to workers was a breakthrough, demonstrating that the use of antibiotics as livestock growth-enhancers was a dangerous practice with significant risks to clinical care. In 1978 he discovered that the mechanism of tetracycline resistance was an energy-dependent antibiotic efflux pump. His research into multiple drug resistance revealed a regulatory locus, mar, for intrinsic antibiotic resistance and virulence among Enterobacteriaceae and other bacteria. He published over 300 papers and edited 4 books devoted to antibiotic use and resistance.
Stuart Levy championed the prudent use of antibiotics and wrote the landmark book, “The Antibiotic Paradox: ‘How Miracle Drugs Are Destroying the Miracle’” now in its second edition and translated into four languages. The ASM book “Frontiers in antimicrobial resistance : a tribute to Stuart B. Levy” was published in 2005 and is based on his work.
Stuart Levy was Chairperson of the U.S. Fogarty Center study of “Antibiotic use and resistance worldwide” and helped write the U.S. Office of Technology Assessment report on antibiotic resistant bacteria. He consulted for international and national organisations including the WHO, the U.S. National Academy of Sciences and Institute of Medicine and the FDA. In 2011 he was presented with ISAC’s highest award, the Hamao Umezawa Memorial Award. Amongst many other accolades, he received the Hoechst Roussel Award for esteemed research in antimicrobial chemotherapy from the ASM and the 2012 Abbott-ASM Lifetime Achievement Award.
APUA is in mourning for its founder and would like to convey heartfelt sympathy to Stuart Levy’s family and friends. He will always be remembered as the father of “antibiotic stewardship” and his legacy will live on through the activities of APUA which ISAC is honored to support.
Professor Pierre Tattevin, APUA Chair
On behalf of The APUA Board
Alliance for the Prudent Use of Antibiotics (APUA)
Now under the auspices of the
International Society of Antimicrobial Chemotherapy (ISAC)
Stuart’s retirement was an opportunity for the APUA Board to review its leadership and governance and it took the opportunity to seek a partner organisation with which to synergise. This led to the merger of APUA with the International Society of Antimicrobial Chemotherapy (ISAC), effective from February 2019. ISAC was founded as a charity in 1961 and, in response to the dynamic nature of the subject matter, has focused most recently on antimicrobial stewardship and antimicrobial resistance.
The boards of the ISAC Antimicrobial Stewardship Working Group and APUA have merged to form the following new APUA Board:
The continuing mission of APUA is to maximise the effectiveness of antimicrobial treatment by promoting appropriate antimicrobial use and containing drug resistance.
APUA and ISAC will retain their own identities.
The launch of APUA under the auspices of ISAC will be kick started with a joint newsletter and reception during ECCMID in Amsterdam in April and the announcement of a new plan of work for APUA.
For more information on ISAC, visit ischemo.org.
Please contact firstname.lastname@example.org for further information.
APUA President Stuart B. Levy announces retirement from Tufts
APUA signs onto REVAMP Act of 2018
Gordon William Grundy, MD (1944-2018)
New U.S. bill introduced to increase oversight of antibiotic use in animals
Canada urges action, federal leadership, for AMR problem
Tripartite memorandum steps up ‘One Health’ agenda
New guidance released for building health worker knowledge and hospital
EU coalition (EU-JAMRA) seeks national action plans for member states
New guidelines issued for C. difficilemanagement
FDA to implement five-year blueprint for antimicrobial stewardship in farm animals
Innovet-AMR: a new partnership seeks alternatives in livestock, aquaculture
Ghana launches antimicrobial resistance policy
Novartis abandons antimicrobial development
Moving beyond antibiotics: the prospects for bacteriophage therapy
Roundworms help identify antibacterial properties of retinoids
Teixobactin development takes ‘quantum leap’
Synthetic polymers as antibiotics
Soil-dwelling nematodes yield novel antimicrobial
Turning MRSA on itself
Using computer algorithms to develop antibiotics
Antibiotic supply chain “fragile” – deepens resistance crisis
Lord O’Neill castigates pharma industry and European farmers for inaction
Repeated low-level antibiotic exposure yields high level resistance
More challenging superbugs on the horizon: pan-resistant infections on the rise
Salmonella typhi approaching pan-resistance
Triple threat posed by Klebsiella
First “super gonorrhea” appears in England
Plasmid transfer found among unrelated hospital bacteria
CPE control — a losing battle?
Mechanics of gene transfer visualized for the first time
Drug users more susceptible to MRSA infection
Microplastics promote gene transfer in aquatic environments
Triclosan exposure yields antibiotic-resistant mutants
Publications of Interest
"Antibiotics are uniquely societal drugs because individual use affects others in the community and environment. Better stewardship, incentives, and establishment of a special regulatory category will improve how they are used, marketed, and developed through incentives to industry."
Stuart B. Levy, M.D.
President of APUA, professor at Tufts University School of Medicine
From the IOM 25th Anniversary Symposium (1996) and The Antibiotic Paradox (2002)
In case you missed it, our latest webinar
is now available for streaming